This program focuses on dissemination of emerging clinical evidence and comprehensive oral and intravenous pharmacotherapy management strategies. The exponential growth of therapies, along with the increased utilization of multiple lines of therapies call for close oversight of rapidly expanding therapeutic options. In addition, advances in diagnostics expanding precision medicine modalities increasingly guide individualized therapy options. With vast emerging scientific evidence on all fronts, it is essential for pharmacists to be equipped with cutting-edged education on evidenced-based treatment options for their patients. This summit also focuses on identifying best practices addressing the unique challenges and opportunities in the local market of Seattle, aiming to leverage patient access to therapies while driving efficiencies and value for all stakeholders involved.

The summit gathers subject matter experts to highlight clinical and practical considerations for emerging specialty pharmaceuticals in a wide variety of oncology and malignant hematology conditions, as well as breakthrough pharmacotherapy advancements in other specialties such as neurology and endocrinology. The content emphasizes the importance and role of the pharmacists in patient adherence. Validated monitoring and adherence tools will be shared as avenues to best manage optimal therapy outcomes.  Furthermore, expert panels will identify potential avenues to drive value through utilization of biosimilars, 505(b)(2) products and other emerging drug classes. Clinical and practical considerations will focus on the challenges and opportunities facing the ecosystem of stakeholders (e.g., patient, pharmacy, payer, manufacturer) that collectively establish access to specialty pharmaceuticals.